Literature DB >> 24433952

[Differential diagnosis of local tumor recurrence or radionecrosis after stereotactic radiosurgery for treatment of brain metastasis].

A Patsouris1, P Augereau1, J-Y Tanguy2, O Morel3, P Menei4, A Rousseau5, A Paumier6.   

Abstract

Magnetic resonance imaging (MRI) is a method of choice for follow-up of irradiated brain metastasis. It is difficult to differentiate local tumour recurrences from radiation induced-changes in case of suspicious contrast enhancement. New advanced MRI techniques (perfusion and spectrometry) and amino acid positron-emission tomography (PET) allow to be more accurate and could avoid a stereotactic biopsy for histological assessment, the only reliable but invasive method. We report the case of a patient who underwent surgery for a single, left frontal brain metastasis of a breast carcinoma, followed by adjuvant stereotactic radiotherapy in the operative bed. Seven months after, she presented a local change in the irradiated area on the perfusion-weighted MRI, for which the differentiation between a local tumour recurrence and radionecrosis was not possible. PET with 2-deoxy-((18)F)-fluoro-D-glucose (FDG) revealed a hypermetabolic lesion. After surgical resection, the histological assessment has mainly recovered radionecrosis with few carcinoma cells. The multimodal MRI has greatly contributed to refine the differential diagnosis between tumour recurrence and radionecrosis, which remains difficult. The FDG PET is helpful, in favour of the diagnosis of local tumour recurrence when a hypermetabolic lesion is found. Others tracers (such as carbon 11 or a fluoride isotope) deserve interest but are not available in all centres. Stereotactic biopsy should be discussed if any doubt remains.
Copyright © 2013 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Brain metastasis; IRM perfusion; Métastases cérébrales; Perfusion RMI; Radionecrosis; Radionécrose; Radiothérapie stéréotaxique; Stereotactic radiotherapy

Mesh:

Substances:

Year:  2014        PMID: 24433952     DOI: 10.1016/j.canrad.2013.10.013

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  3 in total

1.  Radionecrosis of the frontal lobe as a consequence of malignant ethmoid tumor management: incidence, diagnosis, risk factors, prevention and management.

Authors:  N Oker; P Lang; D Bresson; B George; J-P Guichard; M Wassef; E Sauvaget; S Froelich; R Kania; P Herman
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-16       Impact factor: 2.503

2.  [Cerebral radiation necrosis in patients irradiated for nasopharyngeal cancer: report of 3 cases].

Authors:  Abderrahman El Mazghi; Issam Lalya; Kaoutar Loukili; Hanan El Kacemi; Taieb Kebdani; Khalid Hassouni
Journal:  Pan Afr Med J       Date:  2014-09-30

3.  Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial.

Authors:  Paul Lesueur; William Kao; Alexandra Leconte; Julien Geffrelot; Justine Lequesne; Joëlle Lacroix; Pierre-Emmanuel Brachet; Ioana Hrab; Philippe Royer; Bénédicte Clarisse; Dinu Stefan
Journal:  BMC Cancer       Date:  2020-02-22       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.